Chugai Pharmaceutical Co., Ltd.
Native name
Chūgai Seiyaku kabushiki gaisha
Company typePublic KK
IndustryPharmaceutical Industry, Business import, production and development of drugs for medical sales
FoundedMarch 8, 1943; 81 years ago (1943-03-08)
HeadquartersNihonbashi Mitsui Tower, Nihonbashi Muromachi 2-1-1, Chūō, Tokyo
On the registration Headquarter: Tokyo Kita (Tokyo)
Key people
Osamu Nagayama - Chairman and Tatsuro Kosaka - CEO
Revenue72.9 billion capital of 47 million yen. Standalone sales of 329.2 billion yen and 344.8 billion yen consolidated
(December 2007)
ParentHoffmann-La Roche (61.62%) (in Japanese)

Chugai Pharmaceutical Co., Ltd. (中外製薬株式会社, Chūgai Seiyaku kabushiki gaisha) is a drug manufacturer operating in Japan. It is a subsidiary controlled by Hoffmann-La Roche, which owns 62% of the company as of 30 June 2014.[1] The company is headquartered in Tokyo. Osamu Nagayama is the current representative director and chairman. Tatsuro Kosaka is the current representative director, president and CEO.



This is a timeline of important events of Chugai Pharmaceutical.[2]

See also


  1. ^ Cortez, Michelle Fay; Matsuyama, Kanoko (25 August 2014). "Roche Said to Have Decided Against Bid for Rest of Chugai". Bloomberg.
  2. ^ "History of Chugai Pharmaceutical". 23 December 2015. Archived from the original on 1 November 2020. Retrieved 18 June 2019.
  3. ^ Staff (2 March 2015). "Chugai to Co-Develop Athersys' Cell Therapy in Japan in Up-to-$205M Partnership". Genetic Engineering & Biotechnology News (Paper, Vol 35, i 7, p. 12). Retrieved 11 June 2016.
  4. ^ "FDA Approves Treatment for Rare Disease Affecting Optic Nerves, Spinal Cord". U.S. Food and Drug Administration. 17 August 2020. Retrieved 18 August 2020.